This page provides structured dose reference tables for both semaglutide and tirzepatide — covering standard titration schedules, typical compounded vial concentrations, and the syringe volumes those doses require. All tables assume a U-100 insulin syringe unless noted.
These charts are for reference only. Your prescribed titration schedule and vial concentration determine the exact volume you draw. If your concentration differs from the examples shown, use the formula below or the calculator to compute your specific draw volume.
Semaglutide is approved for weight management (Wegovy) and type 2 diabetes (Ozempic). Compounded versions follow the same active ingredient but may differ in concentration. The FDA-approved titration schedule for Wegovy is the most commonly referenced baseline for weight loss dosing.
Semaglutide — Standard Wegovy Titration Schedule
| Weeks | Dose | Phase |
|---|---|---|
| 1–4 | 0.25 mg | Initiation |
| 5–8 | 0.5 mg | Titration |
| 9–12 | 1.0 mg | Titration |
| 13–16 | 1.7 mg | Titration |
| 17+ | 2.4 mg | Maintenance |
Compounded semaglutide prescribers may use a different schedule — slower titration is common for tolerability. The doses above are the approved Wegovy milestones, not a universal requirement. Always follow your prescriber's specific instructions.
Semaglutide — Volume to Draw at Common Concentrations (U-100 Syringe)
Concentration: 1 mg/mL
| Dose | Volume (mL) | U-100 Units |
|---|---|---|
| 0.25 mg | 0.25 mL | 25 units |
| 0.5 mg | 0.50 mL | 50 units |
| 1.0 mg | 1.00 mL | 100 units |
Concentration: 2.5 mg/mL
| Dose | Volume (mL) | U-100 Units |
|---|---|---|
| 0.25 mg | 0.10 mL | 10 units |
| 0.5 mg | 0.20 mL | 20 units |
| 1.0 mg | 0.40 mL | 40 units |
| 1.7 mg | 0.68 mL | 68 units |
| 2.4 mg | 0.96 mL | 96 units |
Concentration: 5 mg/mL
| Dose | Volume (mL) | U-100 Units |
|---|---|---|
| 0.25 mg | 0.05 mL | 5 units |
| 0.5 mg | 0.10 mL | 10 units |
| 1.0 mg | 0.20 mL | 20 units |
| 1.7 mg | 0.34 mL | 34 units |
| 2.4 mg | 0.48 mL | 48 units |
Concentration: 10 mg/mL
| Dose | Volume (mL) | U-100 Units |
|---|---|---|
| 0.5 mg | 0.05 mL | 5 units |
| 1.0 mg | 0.10 mL | 10 units |
| 1.7 mg | 0.17 mL | 17 units |
| 2.4 mg | 0.24 mL | 24 units |
Need help calculating your dose?
Use the GLP-1 dosage calculator.
Tirzepatide is a dual GIP/GLP-1 receptor agonist approved for weight management (Zepbound) and type 2 diabetes (Mounjaro). Its titration schedule spans a wider dose range than semaglutide — from 2.5 mg up to 15 mg weekly. Compounded tirzepatide uses the same milligram doses with variable concentrations.
Tirzepatide — Standard Zepbound / Mounjaro Titration Schedule
| Weeks | Dose | Phase |
|---|---|---|
| 1–4 | 2.5 mg | Initiation |
| 5–8 | 5.0 mg | Titration |
| 9–12 | 7.5 mg | Titration |
| 13–16 | 10.0 mg | Titration |
| 17–20 | 12.5 mg | Titration |
| 21+ | 15.0 mg | Maintenance |
As with semaglutide, prescribers may slow or pause titration based on tolerability. Not all patients reach or require the maximum dose. The schedule above reflects the approved labeling; actual titration is individualized.
Tirzepatide — Volume to Draw at Common Concentrations (U-100 Syringe)
Concentration: 5 mg/mL
| Dose | Volume (mL) | U-100 Units |
|---|---|---|
| 2.5 mg | 0.50 mL | 50 units |
| 5.0 mg | 1.00 mL | 100 units |
Concentration: 10 mg/mL
| Dose | Volume (mL) | U-100 Units |
|---|---|---|
| 2.5 mg | 0.25 mL | 25 units |
| 5.0 mg | 0.50 mL | 50 units |
| 7.5 mg | 0.75 mL | 75 units |
| 10.0 mg | 1.00 mL | 100 units |
Concentration: 25 mg/mL
| Dose | Volume (mL) | U-100 Units |
|---|---|---|
| 2.5 mg | 0.10 mL | 10 units |
| 5.0 mg | 0.20 mL | 20 units |
| 7.5 mg | 0.30 mL | 30 units |
| 10.0 mg | 0.40 mL | 40 units |
| 12.5 mg | 0.50 mL | 50 units |
| 15.0 mg | 0.60 mL | 60 units |
Concentration: 50 mg/mL
| Dose | Volume (mL) | U-100 Units |
|---|---|---|
| 5.0 mg | 0.10 mL | 10 units |
| 7.5 mg | 0.15 mL | 15 units |
| 10.0 mg | 0.20 mL | 20 units |
| 12.5 mg | 0.25 mL | 25 units |
| 15.0 mg | 0.30 mL | 30 units |
Side-by-Side Comparison
| Property | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 agonist | GIP + GLP-1 agonist |
| Starting dose | 0.25 mg | 2.5 mg |
| Max approved dose | 2.4 mg | 15.0 mg |
| Titration steps | 4 steps | 5 steps |
| Injection frequency | Weekly | Weekly |
| Injection route | Subcutaneous | Subcutaneous |
| Brand names (weight) | Wegovy | Zepbound |
| Brand names (diabetes) | Ozempic | Mounjaro |
Common Mistakes
Using semaglutide dose volumes for tirzepatide. Tirzepatide doses are 10–20× higher in milligrams than semaglutide doses. The volume you draw for 2.5 mg of tirzepatide at a given concentration has no relation to what you would draw for 0.25 mg of semaglutide. Always match your dose and concentration to the correct drug.
Assuming concentration is the same across refills. Compounding pharmacies may supply the same drug at different concentrations between batches. A new vial with a different mg/mL value requires a new volume calculation — even if your prescribed dose in mg has not changed. Read every vial label before drawing.
Titrating without prescriber guidance. These charts show approved titration milestones, not self-directed instructions. Moving up a dose level should be confirmed with your prescriber. Slower titration is common and appropriate — tolerance at a given dose does not automatically mean it is time to increase.
Confusing Ozempic doses with Wegovy doses. Ozempic is approved up to 2.0 mg weekly for diabetes. Wegovy reaches 2.4 mg for weight management. The titration schedules differ between indications. If your prescription references one drug's schedule, do not substitute the other's milestones.
Frequently Asked Questions
A weekly journal for logging injections, meals, side effects, and how you feel — no app required.
Get the Journal on AmazonNeed help calculating your dose?
Use the GLP-1 dosage calculator.